BC3195

Phase 2Small molecule

BBiocity Biopharmaceutics Co., Ltd.

BC3195 is one of 38 small molecule programs targeting Metastatic Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic CancerRecruiting

Locally Advanced or Metastatic Solid TumorsNot yet recruiting

Metastatic CancerPhase 1

Recruiting

Locally Advanced or Metastatic Solid TumorsPhase 2

Not yet recruiting

Competition

Competitive Landscape

45 competitors in Locally Advanced or Metastatic Solid Tumors

#DrugCompanyPhaseTrials

Tecentriq

Roche

Phase 2

13 2

Keytruda

Merck & Co.

Phase 2

10 3

Stivarga

Bayer

Phase 2

1 4

Vitrakvi

Bayer

Phase 2

1 5

Afinitor

Novartis

Phase 2

1 6

OPDUALAG

Bristol-Myers Squibb

Phase 2

1 7

Cabometyx

Bristol-Myers Squibb

Phase 1

1 8

Budigalimab

AbbVie

Phase 1

1 9

Livmoniplimab

AbbVie

Phase 1

1 10

Nab-Sirolimus

MMirati Therapeutics Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Metastatic Cancer

NCT06548672

Q4 2028

Phase 1/2Not yet recruiting

Locally Advanced or Metastatic Solid Tumors

NCT07469774

Clinical

Trials by Indication[1]

Metastatic Cancer1 trial

A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer

Recruiting·BBiocity Biopharmaceutics Co., Ltd.·Phase 1·NCT06548672·148 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Not yet recruiting·BBiocity Biopharmaceutics Co., Ltd.·Phase 1/2·NCT07469774·111 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BC3195. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BC3195 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BC3195. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biocity Biopharmaceutics Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBiocity Biopharmaceutics Co., Ltd.

BC3195

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2028

Trials by Indication[1]

Metastatic Cancer1 trial

Locally Advanced or Metastatic Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News